Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Cash (2016 - 2025)

Historic Change in Cash for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $71.7 million.

  • Ligand Pharmaceuticals' Change in Cash rose 5766.71% to $71.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.8 million, marking a year-over-year increase of 7311.53%. This contributed to the annual value of $49.4 million for FY2024, which is 32380.28% up from last year.
  • Ligand Pharmaceuticals' Change in Cash amounted to $71.7 million in Q3 2025, which was up 5766.71% from $19.7 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Change in Cash ranged from a high of $71.7 million in Q3 2025 and a low of -$60.3 million during Q2 2023
  • For the 5-year period, Ligand Pharmaceuticals' Change in Cash averaged around $4.8 million, with its median value being -$1.2 million (2022).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Change in Cash surged by 114658.31% in 2022, and later crashed by 63771.48% in 2023.
  • Ligand Pharmaceuticals' Change in Cash (Quarter) stood at -$3.9 million in 2021, then surged by 1146.58% to $40.9 million in 2022, then tumbled by 92.43% to $3.1 million in 2023, then skyrocketed by 180.62% to $8.7 million in 2024, then skyrocketed by 725.36% to $71.7 million in 2025.
  • Its Change in Cash was $71.7 million in Q3 2025, compared to $19.7 million in Q2 2025 and -$24.3 million in Q1 2025.